Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-701-7901
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.97 million
Profitability
Miscellaneous
Employees146
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. The biopharmaceutical company had revenue of $1.24 million for the quarter, compared to the consensus estimate of $1.97 million. Kindred Biosciences had a negative return on equity of 55.46% and a negative net margin of 1,583.00%. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
8 brokerages have issued 1-year price targets for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they anticipate Kindred Biosciences' share price to reach $14.81 in the next year. This suggests a possible upside of 87.0% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.
What is the consensus analysts' recommendation for Kindred Biosciences?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.
What are Wall Street analysts saying about Kindred Biosciences stock?
Here are some recent quotes from research analysts about Kindred Biosciences stock:
- 1. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (10/9/2019)
- 2. HC Wainwright analysts commented, "We believe a pivotal study for KIND-016 could be similar in design and size to the pivotal study of lokivetmab (Cytopoint, marketed by Zoetis (ZTS; not rated)), an anti-IL31 antibody approved for the treatment of allergic or atopic dermatitis in dogs. The 274-dog pivotal study of lokivetmab evaluated lokivetmab’s non-inferiority compared to an active control, cyclosporine. In this study, lokivetmab achieved mean percentage PVAS reductions of 42.25, 56.86, and 67.38% on weeks 2, 4, and 8, respectively. We note that despite the positive top-line data of KIND-106, it is difficult to compare the KIND-106 efficacy to that of lokivetmab until the company has disclosed the baseline results and we see the full analysis of the complete data." (7/31/2019)
Has Kindred Biosciences been receiving favorable news coverage?
Media coverage about KIN stock has trended somewhat negative recently, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Kindred Biosciences.
Are investors shorting Kindred Biosciences?
Kindred Biosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 930,300 shares, an increase of 9.6% from the August 30th total of 848,700 shares. Based on an average daily volume of 177,800 shares, the days-to-cover ratio is presently 5.2 days. Currently, 2.5% of the shares of the stock are short sold. View Kindred Biosciences' Current Options Chain.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), Dicerna Pharmaceuticals (DRNA), Endo International (ENDP), ArQule (ARQL), Innoviva (INVA), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), Epizyme (EPZM), Theravance Biopharma (TBPH), Amphastar Pharmaceuticals (AMPH) and Odonate Therapeutics (ODT).
What other stocks do shareholders of Kindred Biosciences own?
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
- Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
- Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
- Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
- Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (0.36%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which institutional investors are buying Kindred Biosciences stock?
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $7.92.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $309.36 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.
What is Kindred Biosciences' official website?
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
